Jeffrey Busby - Axim Biotechnologies Sr Devel

All Insiders . USA . 
Stock . Axim Biotechnologies . Stakeholders . Insider . Jeffrey Busby
AXIM Stock  USD 0  0  33.33%   

Insider

Jeffrey Busby is Sr Devel of Axim Biotechnologies
Phone858 923 4422
Webhttps://www.aximbiotech.com

Axim Biotechnologies Management Efficiency

The company has return on total asset (ROA) of (0.3465) % which means that it has lost $0.3465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (100.1909) %, meaning that it created substantial loss on money invested by shareholders. Axim Biotechnologies' management efficiency ratios could be used to measure how well Axim Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities.
Axim Biotechnologies currently holds 5.06 M in liabilities with Debt to Equity (D/E) ratio of 1.36, which is about average as compared to similar companies. Axim Biotechnologies has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Axim Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Axim Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axim Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axim to invest in growth at high rates of return. When we think about Axim Biotechnologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Hejingdao WuAscletis Pharma
49
Julie ACAGH Research PLC
38
George HillAscletis Pharma
72
Ming CPAAscletis Pharma
N/A
Jinzi WuAscletis Pharma
60
Handan HeAscletis Pharma
61
Jean EpinatCellectis SA
N/A
Florian MGH Research PLC
55
John MBAAscletis Pharma
N/A
Kyung NamWortmanCellectis SA
53
Dr MBACellectis SA
46
Valerie CrosCellectis SA
N/A
Kristjan GudmundssonAscletis Pharma
55
Pascalyne WilsonCellectis SA
N/A
MSc MScCellectis SA
54
Yuemei YanAscletis Pharma
53
Theis MDGH Research PLC
48
Magnus HalleGH Research PLC
27
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people. Axim Biotechnologies [AXIM] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity-100.19
Return On Asset-0.35

Axim Biotechnologies Leadership Team

Elected by the shareholders, the Axim Biotechnologies' board of directors comprises two types of representatives: Axim Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axim. The board's role is to monitor Axim Biotechnologies' management team and ensure that shareholders' interests are well served. Axim Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axim Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joseph MD, Chief Board
Catalina JD, I Biotech
Dr MBA, I Biotech
John II, CEO Pres
Robert Malasek, CFO Sec
Jeffrey Busby, Sr Devel
Alim SeitNebi, I Biotech

Axim Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Axim Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-100.19
Return On Asset-0.35
Operating Margin(847.86) %
Current Valuation13.6 M
Shares Outstanding186.44 M
Shares Owned By Insiders40.97 %
Price To Earning(53.71) X
Price To Book2.86 X
Price To Sales943.93 X
Revenue60.46 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Axim Pink Sheet

Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY